Glucose IntoleranceNCT07403864
Effects of Acute Sleep Deprivation on Health
A study testing Normal sleep and Partial sleep deprivation in people with Glucose Intolerance and Energy Expenditure, run by National Taiwan Normal University.
Trial summary
This study will investigate whether various types of regular exercise can provide protective effects against metabolic abnormalities induced by sleep restriction. It will examine responses related to metabolic health, cognitive function, energy expenditure, subjective feelings, and human behaviors, including physical… Read more about this study
- Who is it for?
- Ages 20 to 45 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Glucose Intolerance, Energy Expenditure, Vascular Stiffness
- What is being tested?
- Normal sleep and Partial sleep deprivation
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 48 participants
- Where
- No sites listed yet
- Study dates
- 1 Mar 2026to 1 Mar 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 45 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Age between 20-45 years.
- Body Mass Index (BMI) between 18.5-27 kg/m².
- No sleep-related medical conditions and good sleep quality, defined as a Pittsburgh Sleep Quality Index (PSQI) score ≤ 5.
- Usual bedtime between 22:00-01:00, wake-up time between 06:00-09:00, with an average sleep duration of 7 to 9 hours; chronotype classified as "definitely not evening type" (score ≥ 42 on the Morningness-Eveningness Questionnaire), and no changes in sleep patterns over the past 3 months.
- Without any metabolic or cardiovascular diseases, and not using medications that could affect metabolic responses.
- No specific dietary habits, such as intermittent fasting or a ketogenic diet.
Show all 11Show fewer
- Maintaining a stable weight (no self-reported weight change ± 3 kg) for at least 3 months.
- Resting blood pressure ≤ 130/80 mmHg.
- No smoking or excessive alcohol consumption.
- Not a shift worker.
- No international travel across time zones has occurred within the past 3 months.
Who cannot join
- Special diets (e.g., intermittent fasting, ketogenic diet)
- Recent injuries or contraindications to intense exercise.
About this study
Official title: Effects of Acute Partial Sleep Deprivation on Metabolic Health and Cognitive Function
This study will investigate whether various types of regular exercise can provide protective effects against metabolic abnormalities induced by sleep restriction. It will examine responses related to metabolic health, cognitive function, energy expenditure, subjective feelings, and human behaviors, including physical activity and energy intake.
Read the detailed description
Sleep disturbances are common among the Taiwanese population due to work-related stress, shift work, and academic demands. Poor sleep can impair glucose and lipid metabolism, increasing the risk of cardiovascular disease and type 2 diabetes. This study will investigate whether regular exercise can mitigate these adverse effects. The findings aim to inform diverse exercise intervention strategies tailored to different populations to reduce health risks associated with insufficient sleep.
Participants will be healthy adults aged 20 to 45, categorized according to their habitual activity levels.
- Sedentary: fewer than 7,000 steps per day and no regular exercise in the past 6 months.
- Regular Aerobic Exercise: Running or cycling at least 2-3 times per week for the past 6 months.
- Regular Resistance Exercise: Resistance training performed at least 2-3 times per week for the past 6 months, with minimal aerobic training.
Eligible participants must have regular sleep habits (Pittsburgh Sleep Quality Index [PSQI] ≤ 5), stable body weight (±3% over the past 3 months), no chronic diseases, no smoking or drinking habits, and no special diets.
Prior to the first main trial, participants will complete assessments of V̇O2max and maximal muscle strength within 7 to 14 days before the main trials. They will also record one week of daily physical activity, sleep patterns (including bedtime and wake-up times), and diet (covering two weekdays and one weekend day) to ensure they meet the inclusion criteria.
Day 1:
Physical activity will be restricted to a minimum, with no exercise permitted. Participants may eat freely before 15:00; however, all food intake will be recorded to enable replication prior to the second main trial. Napping is not allowed. Participants will arrive at the laboratory between 18:30 and 19:00. Upon arrival, after a 20-minute rest period, baseline measurements will be conducted, including body composition, waist and hip circumference, vascular function, subjective questionnaires, heart rate variability, food preference, a 20-minute energy metabolism assessment, and cognitive function testing. Subsequently, a standardized dinner will be provided by the researchers and consumed within 25 minutes. Participants will be allowed to wash and prepare between 20:00 and 20:30. From arrival onward, participants will remain seated on the experimental bed throughout the entire laboratory session. Continuous Glucose Monitoring (CGM) will be installed on day 1. Participants will have either an 8-hour sleep opportunity in the laboratory from 23:00 to 07:00 (i.e., normal sleep trial) or a 3-hour sleep opportunity from 03:00 to 07:00 (i.e., partial sleep deprivation trial).
Day 2:
Participants will wake at 07:00. After completing personal hygiene, they will rest for 20 minutes to ensure full wakefulness. At 07:30, a 20-minute resting metabolic rate assessment will be conducted, alongside the collection of heart rate variability and muscle oxygen saturation data. Subsequently, pulse wave velocity measurement, cognitive function tests, and subjective questionnaires will be administered.
This will be followed by a 3-hour oral glucose tolerance test (OGTT), during which 75 g of glucose will be ingested, and muscle oxygen saturation will be continuously monitored. Capillary blood samples will be collected via finger prick at 0, 30, 60, 90, 120, 150, and 180 minutes, alongside continuous glucose monitoring. Resting gas exchange, heart rate variability, and pulse wave velocity will be measured every 60 minutes. Blood pressure and visual analogue scale assessments-including sleep, appetite, and mood-will be recorded every 30 minutes. Cognitive function will be evaluated every 90 minutes.
Upon leaving the laboratory, participants will receive a pedometer and wearable devices. They will be instructed to record their dietary intake (using a food scale and photographic records), sleep patterns, and glucose levels on the experimental day and for the subsequent four consecutive days.
- Conditions
- Glucose Intolerance, Energy Expenditure, Vascular Stiffness, Cognition
- Being tested
- Normal sleep, Partial sleep deprivation
- Keywords
- Partial sleep deprivation, Sleep loss, Physical inactivity, Exercise habits
- Medical subject headings
- Glucose Intolerance, Sedentary Behavior
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Normal sleepBehavioural
Participants will have an 8-hour sleep opportunity in the lab from 23:00 to 07:00.
Partial sleep deprivationBehavioural
Participants will have a 3-hour sleep opportunity in the lab from 03:00 to 07:00.
| Study group | Role | What they receive |
|---|---|---|
| Normal sleep | Experimental | Participants will have an 8-hour sleep opportunity in the lab from 23:00 to 07:00. Receives: Behavioral: Normal sleep |
| Partial sleep deprivation | Experimental | Participants will have a 3-hour sleep opportunity in the lab from 03:00 to 07:00. Receives: Behavioral: Partial sleep deprivation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Glycemic Control
Glucose responses during the 3-hour oral glucose tolerance test (OGTT)
Measured: Baseline measurements and continuously at regular intervals throughout the 3-hour OGTT.
Pulse wave velocity (PWV)
Pulse wave velocity assessments (i.e., meters per second) will be collected before and during the 3-hour oral glucose tolerance test (OGTT).
Measured: 0 (baseline), 60, 120 and 180 minutes during OGTT
Cognitive function (Accuracy)
Accuracy (i.e., %) in computerized tests will be tested before and during the 3-hour oral glucose tolerance test (OGTT).
Measured: 0 (baseline), 90 and 180 minutes during OGTT
Cognitive function (Reaction time)
Reaction time (i.e., milliseconds) in computerized tests will be tested before and during the 3-hour oral glucose tolerance test (OGTT).
Measured: 0 (baseline), 90 and 180 minutes during OGTT
Secondary outcomes (6)
Resting energy expenditure
Energy expenditure will be collected before and during the 3-hour oral glucose tolerance test (OGTT).
Measured: 0 (baseline), 60, 120 and 180 minutes during OGTT
Carbohydrate oxidation
Carbohydrate oxidation will be collected before and during the 3-hour oral glucose tolerance test (OGTT).
Measured: 0 (baseline), 60, 120 and 180 minutes during OGTT
Fat oxidation
Fat oxidation will be collected before and during the 3-hour oral glucose tolerance test (OGTT).
Measured: 0 (baseline), 60, 120 and 180 minutes during OGTT
Heart rate variability
Heart rate variability will be collected before and during the 3-hour oral glucose tolerance test (OGTT).
Measured: 0 (baseline), 60, 120 and 180 minutes during OGTT
Muscle oxygen saturation
Muscle oxygen saturation data will be collected before and during the 3-hour oral glucose tolerance test (OGTT).
Measured: 0 minute (baseline) and throughout the entire 3-hour OGTT
Blood pressure
Blood pressure (mmHg) assessments will be collected before and during the 3-hour oral glucose tolerance test (OGTT).
Measured: 0 (baseline), 30, 60, 90, 120,150 and 180 minutes during OGTT
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Feb 2026
- Study start1 Mar 2026 (estimated)
- Primary completion1 Mar 2027 (estimated)
- Study completion1 Mar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Glucose IntoleranceStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 48 participants (estimated)
Sponsor and investigators
- Lead sponsor
- National Taiwan Normal University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Yung-Chih Chen, National Taiwan Normal University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07403864
- Sponsor's protocol ID
- 202412HM033
- Status last verified
- Feb 2026
- First submitted
- 23 Jan 2026
- Last updated
- 11 Feb 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Acute Partial Sleep Deprivation on Metabolic Health and Cognitive Function
- ClinicalTrials.gov ID
- NCT07403864
- Acronym / sponsor ID
- 202412HM033
- Conditions
- Glucose Intolerance, Energy Expenditure, Vascular Stiffness, Cognition
- Keywords
- Partial sleep deprivation, Sleep loss, Physical inactivity, Exercise habits
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 48 participants (estimated)
- Lead sponsor
- National Taiwan Normal UniversityUniversity, hospital or other
- Study start
- 1 Mar 2026 (estimated)
- Primary completion
- 1 Mar 2027 (estimated)
- Study completion
- 1 Mar 2027 (estimated)
- First posted
- 11 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will investigate whether various types of regular exercise can provide protective effects against metabolic abnormalities induced by sleep restriction. It will examine responses related to metabolic health, cognitive function, energy expenditure, subjective feelings, and human behaviors, including physical activity and energy intake.
Detailed description
Sleep disturbances are common among the Taiwanese population due to work-related stress, shift work, and academic demands. Poor sleep can impair glucose and lipid metabolism, increasing the risk of cardiovascular disease and type 2 diabetes. This study will investigate whether regular exercise can mitigate these adverse effects. The findings aim to inform diverse exercise intervention strategies tailored to different populations to reduce health risks associated with insufficient sleep.
Participants will be healthy adults aged 20 to 45, categorized according to their habitual activity levels.
- Sedentary: fewer than 7,000 steps per day and no regular exercise in the past 6 months.
- Regular Aerobic Exercise: Running or cycling at least 2-3 times per week for the past 6 months.
- Regular Resistance Exercise: Resistance training performed at least 2-3 times per week for the past 6 months, with minimal aerobic training.
Eligible participants must have regular sleep habits (Pittsburgh Sleep Quality Index [PSQI] ≤ 5), stable body weight (±3% over the past 3 months), no chronic diseases, no smoking or drinking habits, and no special diets.
Prior to the first main trial, participants will complete assessments of V̇O2max and maximal muscle strength within 7 to 14 days before the main trials. They will also record one week of daily physical activity, sleep patterns (including bedtime and wake-up times), and diet (covering two weekdays and one weekend day) to ensure they meet the inclusion criteria.
Day 1:
Physical activity will be restricted to a minimum, with no exercise permitted. Participants may eat freely before 15:00; however, all food intake will be recorded to enable replication prior to the second main trial. Napping is not allowed. Participants will arrive at the laboratory between 18:30 and 19:00. Upon arrival, after a 20-minute rest period, baseline measurements will be conducted, including body composition, waist and hip circumference, vascular function, subjective questionnaires, heart rate variability, food preference, a 20-minute energy metabolism assessment, and cognitive function testing. Subsequently, a standardized dinner will be provided by the researchers and consumed within 25 minutes. Participants will be allowed to wash and prepare between 20:00 and 20:30. From arrival onward, participants will remain seated on the experimental bed throughout the entire laboratory session. Continuous Glucose Monitoring (CGM) will be installed on day 1. Participants will have either an 8-hour sleep opportunity in the laboratory from 23:00 to 07:00 (i.e., normal sleep trial) or a 3-hour sleep opportunity from 03:00 to 07:00 (i.e., partial sleep deprivation trial).
Day 2:
Participants will wake at 07:00. After completing personal hygiene, they will rest for 20 minutes to ensure full wakefulness. At 07:30, a 20-minute resting metabolic rate assessment will be conducted, alongside the collection of heart rate variability and muscle oxygen saturation data. Subsequently, pulse wave velocity measurement, cognitive function tests, and subjective questionnaires will be administered.
This will be followed by a 3-hour oral glucose tolerance test (OGTT), during which 75 g of glucose will be ingested, and muscle oxygen saturation will be continuously monitored. Capillary blood samples will be collected via finger prick at 0, 30, 60, 90, 120, 150, and 180 minutes, alongside continuous glucose monitoring. Resting gas exchange, heart rate variability, and pulse wave velocity will be measured every 60 minutes. Blood pressure and visual analogue scale assessments-including sleep, appetite, and mood-will be recorded every 30 minutes. Cognitive function will be evaluated every 90 minutes.
Upon leaving the laboratory, participants will receive a pedometer and wearable devices. They will be instructed to record their dietary intake (using a food scale and photographic records), sleep patterns, and glucose levels on the experimental day and for the subsequent four consecutive days.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Normal sleep | Experimental | Behavioral: Normal sleepParticipants will have an 8-hour sleep opportunity in the lab from 23:00 to 07:00. |
| Partial sleep deprivation | Experimental | Behavioral: Partial sleep deprivationParticipants will have a 3-hour sleep opportunity in the lab from 03:00 to 07:00. |
Who may qualify
- Ages
- 20 to 45 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (11 listed)
- Age between 20-45 years.
- Body Mass Index (BMI) between 18.5-27 kg/m².
- No sleep-related medical conditions and good sleep quality, defined as a Pittsburgh Sleep Quality Index (PSQI) score ≤ 5.
- Usual bedtime between 22:00-01:00, wake-up time between 06:00-09:00, with an average sleep duration of 7 to 9 hours; chronotype classified as "definitely not evening type" (score ≥ 42 on the Morningness-Eveningness Questionnaire), and no changes in sleep patterns over the past 3 months.
- Without any metabolic or cardiovascular diseases, and not using medications that could affect metabolic responses.
Key exclusion criteria (2 listed)
- Special diets (e.g., intermittent fasting, ketogenic diet)
- Recent injuries or contraindications to intense exercise.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Normal sleepParticipants will have an 8-hour sleep opportunity in the lab from 23:00 to 07:00. | Behavioural | Normal sleep |
| Partial sleep deprivationParticipants will have a 3-hour sleep opportunity in the lab from 03:00 to 07:00. | Behavioural | Partial sleep deprivation |
Primary outcome
Glycemic Control
Time frame: Baseline measurements and continuously at regular intervals throughout the 3-hour OGTT.
Glucose responses during the 3-hour oral glucose tolerance test (OGTT)
Pulse wave velocity (PWV)
Time frame: 0 (baseline), 60, 120 and 180 minutes during OGTT
Pulse wave velocity assessments (i.e., meters per second) will be collected before and during the 3-hour oral glucose tolerance test (OGTT).
Cognitive function (Accuracy)
Time frame: 0 (baseline), 90 and 180 minutes during OGTT
Accuracy (i.e., %) in computerized tests will be tested before and during the 3-hour oral glucose tolerance test (OGTT).
Cognitive function (Reaction time)
Time frame: 0 (baseline), 90 and 180 minutes during OGTT
Reaction time (i.e., milliseconds) in computerized tests will be tested before and during the 3-hour oral glucose tolerance test (OGTT).
6 secondary outcomes
Resting energy expenditure
Time frame: 0 (baseline), 60, 120 and 180 minutes during OGTT
Carbohydrate oxidation
Time frame: 0 (baseline), 60, 120 and 180 minutes during OGTT
Fat oxidation
Time frame: 0 (baseline), 60, 120 and 180 minutes during OGTT
Heart rate variability
Time frame: 0 (baseline), 60, 120 and 180 minutes during OGTT
Muscle oxygen saturation
Time frame: 0 minute (baseline) and throughout the entire 3-hour OGTT
Blood pressure
Time frame: 0 (baseline), 30, 60, 90, 120,150 and 180 minutes during OGTT
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Feb 2026.
Related trials for Glucose Intolerance
Recruiting
Effects of Lean Pork Loin Intake on Protein Homeostasis and Glucose Regulation in Prediabetic Adults
Hyperglycaemia (Non Diabetic), Prediabetes
RecruitingObservational study
Food-i-Sense Analytics: Integrating AI Into Continuous Glucose Monitoring Data Analysis for Precision Nutrition.
Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Artificial Intelligence Mobile Application
Enrolling by invitationEarly Phase 1
Truway Diagnostic Tools in Primary Care
Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Recruiting
CGM-Enhanced DPP to Prevent Type 2 Diabetes in Adults With Prediabetes
PreDiabetes
Active, not recruitingPhase 2
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
Cushing Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing Normal sleep and Partial sleep deprivation in people with Glucose Intolerance and Energy Expenditure, run by National Taiwan Normal University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 11 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Glycemic Control (time frame: Baseline measurements and continuously at regular intervals throughout the 3-hour OGTT.). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Feb 2026.